Skip to main content
Captor Therapeutics S.A. logo

Captor Therapeutics S.A. — Investor Relations & Filings

Ticker · CTX ISIN · PLCPTRT00014 LEI · 259400JHH1S2I2S4O735 WAR Professional, scientific and technical activities
Open in API
Filings indexed 920 across all filing types
Latest filing 2026-02-03 Proxy Solicitation & In…
Country PL Poland
Listing WAR CTX

About Captor Therapeutics S.A.

https://www.captortherapeutics.com/

Captor Therapeutics is a biopharmaceutical company focused on the discovery and development of novel therapeutics for diseases with high unmet medical needs. The company specializes in Targeted Protein Degradation (TPD), a technology that enables the elimination of disease-causing proteins previously considered "undruggable." Its core research and development activities are centered on creating new treatments for cancer and autoimmune diseases. To achieve this, Captor Therapeutics utilizes its proprietary Optigrade™ platform. This integrated drug discovery engine combines advanced technologies, including structural biology, proteomics, molecular modeling, and protein engineering, to identify and optimize novel drug candidates. The platform is designed to accelerate the development of degraders with superior therapeutic properties, aiming to provide new treatment options for severe conditions.

Recent filings

Filing Released Lang Actions
załącznik nr 4 - wzór pełnomocnictwa
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Formularz Pełnomocnictwa' (Proxy Form) for an Extraordinary General Meeting (Nadzwyczajne Walne Zgromadzenie) of Captor Therapeutics S.A. Proxy forms are standard materials provided to shareholders to enable them to vote by proxy at a meeting. This falls under the category of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to request votes for meetings.
2026-02-03 Polish
załącznik nr 3 - opinia Zarządu
Capital/Financing Update Classification · 95% confidence The document is a 'Written Opinion of the Management Board' regarding the exclusion of pre-emptive rights for a new series of shares (Series Y) and the method for determining the issue price. This type of document is a formal corporate governance and capital structure filing required under the Polish Commercial Companies Code. It relates directly to the issuance of new shares and capital changes, which falls under the 'Share Issue/Capital Change' category.
2026-02-03 Polish
załącznik nr 2 - projekty uchwał ZNWZ
Share Issue/Capital Change Classification · 98% confidence The document contains the draft resolutions for an Extraordinary General Meeting (Nadzwyczajne Walne Zgromadzenie) of 'CAPTOR THERAPEUTICS' S.A. It details specific agenda items, including the election of a chairman, approval of the agenda, and a significant resolution regarding a capital increase through the issuance of new shares (Series Y) and the exclusion of subscription rights. These materials are provided to shareholders to inform them of the matters to be voted upon at the upcoming meeting. This fits the definition of Proxy Solicitation & Information Statement (PSI) as it provides the necessary information for shareholders to exercise their voting rights.
2026-02-03 Polish
załącznik nr 1 - ogłoszenie
Proxy Solicitation & Information Statement Classification · 100% confidence The document is an official notice ('OGŁOSZENIE') from Captor Therapeutics S.A. regarding the convocation of an Extraordinary General Meeting (Nadzwyczajne Walne Zgromadzenie). It details the date, time, location, agenda, and procedures for shareholder participation, voting, and proxy representation. This document is a standard proxy solicitation and information statement provided to shareholders to inform them of an upcoming meeting and request their participation/votes.
2026-02-03 Polish
Ogłoszenie o zwołaniu Nadzwyczajnego Walnego Zgromadzenia oraz dokumenty związane z Nadzwyczajnym Walnym Zgromadzeniem - Content (PL)
Capital/Financing Update Classification · 95% confidence The document is a formal notice from Captor Therapeutics S.A. announcing an Extraordinary General Meeting (Nadzwyczajne Walne Zgromadzenie). It includes the agenda, draft resolutions, and proxy materials as attachments. While it discusses capital increase plans, the primary purpose of the filing is to provide shareholders with the necessary information and materials for the upcoming meeting, which aligns with the definition of a Proxy Solicitation & Information Statement.
2026-02-03 Polish
Rejestracja podwyższenia kapitału zakładowego i zmian w Statucie Spółki - Content (PL)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement by Captor Therapeutics S.A. regarding the registration of changes to its company statute by the court. These changes relate to a capital increase and the issuance of new shares (Series W) as well as the establishment of a new incentive program. This falls under the category of share issuance and capital structure changes, which is explicitly defined as 'Share Issue/Capital Change' (SHA).
2026-01-22 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.